Медицинская библиотека · Multiple sclerosis and related disorders · 2022

Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study.

Gold Julian, Holden David, Parratt John, Yiannikas Con, Ahmad Raghib, Sedhom Mamdouh, Giovannoni Gavin

Письмо в редакциюПеревод в очереди

Аннотация

BACKGROUND

Given its potential antiviral activity, we investigated the effect of teriflunomide on EBV in patients with relapsing-remitting MS (RRMS).

METHODS

Saliva samples were collected at home and analysed for EBV DNA presence in patients with RRMS treated with teriflunomide for ≥3 months.

RESULTS

The proportion of patients with detectable EBV in the teriflunomide cohort was lower than in the reference cohorts. The proportion of samples with EBV DNA or shedding from teriflunomide-treated patients was reduced relative to each reference cohort (P<0.0001; >5.8 virus copies/µL cut-off).

CONCLUSION

This pilot study demonstrated the feasibility of at-home saliva sample collection and revealed a possible effect of teriflunomide on EBV shedding.

Для цитирования: Gold Julian, Holden David, Parratt John, Yiannikas Con, Ahmad Raghib, Sedhom Mamdouh, Giovannoni Gavin. Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study.. Multiple sclerosis and related disorders. 2022. DOI: 10.1016/j.msard.2022.104377.

Предметные рубрики MeSH

Humans Multiple Sclerosis, Relapsing-Remitting Herpesvirus 4, Human Pilot Projects Multiple Sclerosis Epstein-Barr Virus Infections Crotonates Cohort Studies Hydroxybutyrates Nitriles Toluidines

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.